Reasons to invest in Oasmia

Oasmia is a specialty pharmaceutical company dedicated to improving the lives of patients by enhancing the solubility & side effect profiles of established & novel drugs in diseases including cancer.

Why invest?

  • Dedicated to building a profitable specialty pharma company targeting unmet medical needs by enhancing the solubility and reducing side effects of established and novel drugs
  • Proven technology with ability to increase R&D efficiency and expand pipeline
  • Lead product Apealea® for advanced ovarian cancer approved in Europe with global partnership with Elevar Therapeutics worth up to USD 678 million plus royalties
  • A growing pipeline underpinned by robust intellectual property protection and strong cash position
  • Experienced management implementing a clear strategy to build a sustainable, profitable business focused on best returns for shareholders
  • Streamlined organization with proven development, regulatory and business-development skills well positioned for M&A, in/out licensing

“Oasmia has a strong cash position, a product approved in Europe with global potential and multiple near-term value drivers in the pipeline. Our product-development and commercialization expertise ideally positions us to pursue high value M&A, business development and partnering opportunities.”

  • 2 nd most common

    Cancer is the 2nd most common cause of death1

  • 18 million people

    18 million people were diagnosed with cancer in 20181

  • USD 240 billion

    The total expenditure on oncology worldwide in 2023 is estimated to be USD 240 billion2

1 World Cancer Research Fund
2 Global Oncology Trends 2019 – Therapeutics, Clinical Development and Health System Implications. IQVIA Institute for Human Data Science.

Key Value Drivers

Near-term (12 months)

  • Elevar partnering for Apealea®️ in Europe, China
  • Apealea®️ royalties
  • Docetaxel micellar Phase 1 initiation
  • Review of Animal Health assets
  • XR-17TM partnering
  • M&A opportunities
  • XR-19 value assessment

Mid-term (12-24 months)

  • Apealea®️ milestones and royalties
  • Docetaxel micellar Phase 1 results / potential Phase 2 initiation
  • Potential initiation of XR-19 program
  • Strengthening of balance sheet through existing cost control measures
  • M&A and in-licensing opportunities to build critical mass